
UK privately-held biotech RQ Bio has announced the appointment of Gavin Koh as chief medical officer (CMO).
Dr Koh brings 20 years of pharmaceutical industry drug development and infectious diseases experience. Prior to joining RQ Bio, he held senior roles at UK pharma majors AstraZeneca (LSE: AZN) and GSK, (LSE: GSK) leading programs from discovery to registration and launch, including Evusheld during the COVID-19 pandemic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze